NBIX · Neurocrine Biosciences Inc
Price
Snapshot
50 fields · last close| Market Cap | $14.43B |
| P/E | 20.39 |
| Float | 99.35M |
| Beta | 0.34 |
| Volatility | 8.4% |
| Exchange | NASDAQ |
| Sector | Biotechnology |
| Cap tier | Large cap |
| Macro sensitivity | Low |
| Clavix score | 79.4 |
| Price | 141.35 |
| Change | −0.46% |
| Prev Close | 142.00 |
| Open | 138.51 |
| Day Low | 137.90 |
| Day High | 142.09 |
| Avg Vol | 1 |
| Avg $ Vol | $178.6M |
| 52W High | 186.12 |
| 52W Low | 122.14 |
| 52W Pos | 30.0% |
| From High | −24.05% |
| From Low | +15.73% |
| Max DD 1Y | −27.15% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | +0.88% |
| SMA 50 | −4.67% |
| SMA 200 | −3.86% |
| RSI (14) | 48.3 |
| Vol 30D | 29.9% |
| Vol 90D | 33.1% |
| 1Y Range | 122–186 |
| Daily bars | 538 |
| Perf Week | +5.08% |
| Perf Month | −1.36% |
| Perf Quarter | −17.77% |
| Perf Half Y | +9.05% |
| Perf Year | +1.36% |
| Perf YTD | +0.53% |
| Prev Day | −0.46% |
| Clavix | B+ |
| Debt / Eq | 0.00 |
| Curr Ratio | 3.39 |
| Int Cover | 3.0× |
| FCF Margin | 26.2% |
| Rev Growth | +21.4% |
| Profit | Profitable |
| Leverage | Low |
| Sector rank | 6 / 35 |
Clavix risk grade
regraded every trading dayNBIX grades B+, 79.4 of 100. Steadiest on Macro Resilience (71), most exposed on Price Stability (62, mixed). 2 of the 4 weighted dimensions sit above the Biotechnology median. Ranks 6 of 35 in Biotechnology by Clavix score.
How rough the ride is
| NBIX | Biotechnology median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 0.34 | 0.51 |
| Volatilityannualized | 8.4% | 14.5% |
| Max drawdown, past yearworst peak-to-trough fall | −27.2% | — |
| Typical daily movemedian absolute daily change | 1.12% | — |
| Days beyond ±3%of the last 252 sessions | 30 (12%) | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| NBIX | Biotechnology median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 0.34 | 0.51 |
| Macro sensitivityrate, dollar and credit exposure bucket | Low | Low 53% of 36 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Biotechnology names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| NBIX | |
|---|---|
| 1 week | +5.1% |
| 1 month | −1.4% |
| Year to date | +0.5% |
| 1 year | +1.4% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| NBIX | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30 since 9 Aug |
| Average score0 most bearish, 100 most bullish | 56 |
| Bullish · bearisharticles above 60 · below 40 | 18 · 7 |
| Directionarticles whose tone is improving vs worsening | 18 ↑ 7 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 36 Biotechnology names Clavix covers; the tick is the sector median.
Growth
| NBIX | |
|---|---|
| Revenue growthyear over year | +21.4% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Biotechnology median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openNeurocrine Biosciences initiated a Phase 2 study of oral NBI-1117567, also called NBI-'567, as an add-on treatment for cognitive impairment in adults with mild to moderate Alzheimer's disease. The drug activates muscarinic M1 and M4 receptors, with a preference for M1.
Neurocrine Biosciences presented real-world medical record evidence showing how the challenges of living with classic congenital adrenal hyperplasia (a genetic hormone disorder present from birth) shift from childhood, where growth and bone-age are tracked, through adulthood, where puberty and reproductive health become concerns.
Neurocrine Biosciences announced new real-world data showing how the clinical and day-to-day burden of classic congenital adrenal hyperplasia (CAH) changes from childhood through adulthood, based on decades of patient medical records. The findings will be presented at the Endocrine Nurses Society Annual Symposium on Oct. 16-17, 2026, in Phoenix.
Patient advocates and some experts are publicly raising safety concerns about Neurocrine Biosciences' rare disease drug Vykat XR, which is used to treat Prader-Willi syndrome (a condition that causes constant feelings of hunger). Since Vykat XR was approved 18 months ago, regulators have received case reports of seven deaths and nearly 100 hospitalizations among people taking it. Reports to regulators do not prove the drug caused these events, and many cases involved complex medical issues and multiple medications, though some experts argue the evidence is enough to show unacceptable harm.
Patient advocates and experts are raising alarms about safety issues with Vykat XR, a Neurocrine Biosciences drug approved to treat Prader-Willi syndrome (a rare disorder causing extreme hunger). Since the drug was approved 18 months ago, seven deaths and nearly 100 hospitalizations have been linked to it, though case reports do not prove the drug caused these events.
Nearest peers by size
Biotechnology| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| ASND | Ascendis Pharma A/S | B+ | $14.62B | 17.25 | 0.39 | Compare |
| HALO | Halozyme Therapeutics Inc | B | $14.12B | 33.62 | 0.93 | Compare |
| BBIO | BridgeBio Pharma Inc | B | $13.21B | — | 0.95 | Compare |
| EXEL | Exelixis Inc | B+ | $15.95B | 18.43 | 0.44 | Compare |
| MDGL | Madrigal Pharmaceuticals Inc | B | $10.80B | — | -1.08 | Compare |
| INSM | Insmed Inc | C | $20.89B | — | 0.83 | Compare |
| KRYS | Krystal Biotech Inc | B | $9.63B | 40.03 | 0.65 | Compare |
| TWST | Twist Bioscience Corp | D+ | $9.39B | — | 2.19 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. 1 month free on iPhone.